Valuation: Summit Therapeutics Inc.

Market Cap 8.69B 11.56B 10.37B 9.58B 16.23B 1,098B 16.43B 115B 45.61B 575B 43.39B 42.46B 1,825B P/E 2026 *
-12.6x
P/E 2027 * -12.4x
Enterprise Value 8.42B 11.21B 10.06B 9.29B 15.74B 1,065B 15.94B 111B 44.23B 558B 42.08B 41.18B 1,770B EV / Sales 2026 *
2,869x
EV / Sales 2027 * 207x
Free-Float
19.32%
Yield 2026 *
-
Yield 2027 * -
1 day+5.17%
1 week-5.13%
Current month-9.73%
1 month-1.39%
3 months+16.48%
6 months-30.99%
Current year-12.72%
1 week 14.37
Extreme 14.37
16.35
1 month 14.37
Extreme 14.37
19.09
Current year 12.07
Extreme 12.07
29.23
1 year 12.07
Extreme 12.07
29.23
3 years 1.64
Extreme 1.64
36.91
5 years 0.66
Extreme 0.66
36.91
10 years 0.66
Extreme 0.66
36.91
Manager TitleAgeSince
Chief Executive Officer 55 24/07/2022
Chief Executive Officer 81 31/03/2020
Director of Finance/CFO 48 01/04/2024
Director TitleAgeSince
Chairman 81 31/01/2020
Director/Board Member 48 30/11/2019
Director/Board Member 55 10/11/2020
Date Insider Type Main position Quantity % Market Cap. Importance
08/10/26 Free

Controller/Auditor

100,000 0.0125%
04/06/26 Buy

Chief Executive Officer

100,000 0.0129%
04/06/26 Buy

Chief Executive Officer

100,000 0.0129%
Change 5-day change 1-year change 3-year change Capi.($)
+5.28%-5.13%-21.56%+743.37% 11.6B
-3.10%-3.43%+36.29%+67.69% 65.28B
+0.33%+0.33%+10.16%+78.07% 54.57B
+0.16%+1.73%+9.89%+102.10% 53.59B
-0.16%+1.99%+25.64%+51.81% 45.03B
-1.48%-4.91%+15.91%+114.51% 42.17B
+1.30%-5.15%+221.50%+901.80% 39.42B
-0.74%-4.84%+14.53%+44.45% 32.71B
-2.70%-7.34%+23.17%+0.36% 24.01B
+1.11%+15.18%+60.27%+49.33% 26.5B
Average -0.02%+1.09%+39.58%+215.35% 39.49B
Weighted average by Cap. -0.51%+1.47%+41.50%+172.84%

Financials

2026 *2027 *
Net sales 2.94M 3.91M 3.51M 3.24M 5.49M 371M 5.55M 38.82M 15.42M 195M 14.67M 14.35M 617M 41.93M 55.8M 50.08M 46.24M 78.37M 5.3B 79.34M 554M 220M 2.78B 209M 205M 8.81B
Net income -697M -927M -832M -768M -1.3B -88.05B -1.32B -9.21B -3.66B -46.15B -3.48B -3.41B -146B -738M -982M -882M -814M -1.38B -93.31B -1.4B -9.76B -3.88B -48.91B -3.69B -3.61B -155B
Net Debt -262M -349M -313M -289M -490M -33.11B -496M -3.46B -1.38B -17.35B -1.31B -1.28B -55.03B -1.6M -2.13M -1.91M -1.76M -2.99M -202M -3.03M -21.14M -8.4M -106M -7.99M -7.82M -336M
Projected Income Statement - Annual - Summit Therapeutics Inc.
Logo Summit Therapeutics Inc.
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.
Employees
265
Date Price Change Volume
27/10/26 US$15.27 +5.31% 3,336,278
26/10/26 US$14.50 -6.27% 4,782,986
23/10/26 US$15.47 -0.51% 3,210,684
22/10/26 US$15.55 -1.77% 4,150,760
21/10/26 US$15.83 -1.62% 5,366,558
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
MarketScreener Ratings - Summit Therapeutics Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
10.86GBP
Average target price
22.58GBP
Spread / Average Target
+107.85%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Summit Therapeutics Inc.
  1. Stock Market
  2. Stocks
  3. SMMT Stock